Therapeutic Equivalence vs. Pharmaceutical Quality [Design Issues]

posted by kumarnaidu – Mumbai, India, 2014-03-15 12:36 (4484 d 13:25 ago) – Posting: # 12634
Views: 6,608

Dear All,

We have submitted old tramadol study recently in EU that was conducted as per the old EMA GL. As per the current GL, for establishing BE we have to consider enantiomers of tramadol and its active metabolite. And hence we have recieved the following query from the agency asking the same.
The use of an achiral bioanalytical method for tramadol and its metabolite should be discussed and justified.
Can anyone help me out to defend this ?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
123 visitors (0 registered, 123 guests [including 28 identified bots]).
Forum time: 03:02 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5